Form 4: Compass Therapeutics Director Granted 90,000 Stock Options

Compass Therapeutics, Inc. Director Ellen Chiniara was granted 90,000 stock options with an exercise price of $5.17, vesting by June 2026.

Summary

• Ellen Chiniara, a Director of Compass Therapeutics, Inc. (CMPX), was granted 90,000 stock options.
• The transaction date for this grant was January 2, 2026.
• Each stock option has an exercise price of $5.17.
• The options are exercisable starting January 2, 2026, and expire on January 2, 2036.
• The grant vests in full upon the earlier of June 10, 2026, or the date of the next annual meeting of the Company's stockholders.
• Following this transaction, Ellen Chiniara beneficially owns 90,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event for a director, which is generally a neutral to slightly positive development as it aligns insider interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operational status.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued commitment and service from the director.

Future Outlook

The stock option grant, with its vesting schedule, indicates an expectation of continued service from the director and aims to align their future financial interests with the company's performance over the vesting period, which extends at least until June 2026 or the next annual meeting.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of non-employee director compensation. It is designed to attract and retain qualified board members and align their long-term interests with shareholder value creation, particularly in sectors with long development cycles and high risk/reward profiles like biotech.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a standard compensation practice across publicly traded companies, especially prevalent in growth-oriented sectors like biotechnology.
• The size of the grant (90,000 options) and the exercise price relative to the current stock price (implied by the grant date) would typically be evaluated against peer companies in the biotech sector to assess if it falls within competitive compensation ranges for directors of similar-sized companies.

Related Party Transactions

• The grant of 90,000 stock options to Ellen Chiniara, a Director of Compass Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board of directors. This is a standard form of director compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with long-term shareholder value creation, potentially leading to more focused decision-making for the company's benefit.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The stock options will vest in full upon the earlier of June 10, 2026, or the date of the next annual meeting of the Company's stockholders.
• The director may choose to exercise the vested options at any point before their expiration date of January 2, 2036.

Key Dates

Keywords

Compass Therapeutics, CMPX, Stock Option, Director Compensation, Equity Grant, Insider Transaction, Form 4, Biotechnology